Related Experiment Video
Updated: Jun 29, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Clinical markers of therapeutic response to disease modifying drugs
Carlo Pozzilli1, Luca Prosperini
1S. Andrea Hospital, La Sapienza University, Via di Grottarossa, 1035, 00189, Rome, Italy. Carlo.Pozzilli@uniroma1.it
Abstract:
Interferon beta (IFNbeta) and glatiramer acetate (GA) showed a relevant impact in modifying the clinical course of relapsing-remitting multiple sclerosis. However, not all treated patients experience a satisfied response to therapy in terms of suppression of relapse and slowing disability progression.At the present time none of the proposed criteria of response to disease modifying therapies (DMTs) have been validated. Clinical parameters, such as relapse rate and disability progression assessing with EDSS scale, may represent two useful indicators of therapeutic response, but their value in predicting the long-term response to DMTs is weak.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Measurement of Bioavailability: Pharmacodynamic Methods
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring: Drug Analysis Methods
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)